References of "Krzesinski, Jean-Marie"
     in
Bookmark and Share    
See detailL'hypertension artérielle chez le diabétique
Krzesinski, Jean-Marie ULg

Conference (2002, May 16)

Detailed reference viewed: 17 (0 ULg)
See detailQue faire face à une hypertension artérielle résistante?
Krzesinski, Jean-Marie ULg

Learning material (2002)

Detailed reference viewed: 13 (1 ULg)
Full Text
Peer Reviewed
See detailLa sténose d'artère rénale: cause possible de décompensation cardiaque aiguë
Krzesinski, Jean-Marie ULg

in Revue Médicale de Liège (2002), 57(5), 253-257

Among the different causes of pulmonary edema, there are all the clinical situations with hydrosaline overload. A significant (> 70%) bilateral renal artery stenosis or a unilateral stenosis in the ... [more ▼]

Among the different causes of pulmonary edema, there are all the clinical situations with hydrosaline overload. A significant (> 70%) bilateral renal artery stenosis or a unilateral stenosis in the presence of a solitary kidney is one possibility. Recurrent acute pulmonary edema not fully explained on a cardiac basis is rather typical for such a disease in a cardiac patient with moderate renal failure aggravated when angiotensin converting enzyme inhibitors are used. [less ▲]

Detailed reference viewed: 119 (3 ULg)
See detailHypertension artérielle et accident vasculaire cérébral
Krzesinski, Jean-Marie ULg

Conference (2002, April 18)

Detailed reference viewed: 37 (17 ULg)
Full Text
Peer Reviewed
See detailQualité de la prise en charge de l'hypertension artérielle. Pouvons-nous, devons-nous faire mieux?
Krzesinski, Jean-Marie ULg

in Revue Médicale de Liège (2002), 57(4), 202-206

Hypertension is well controlled in only less than 30% of the patients treated by drugs. It is thus important to improve this situation first by checking the treatment compliance but also by trying to ... [more ▼]

Hypertension is well controlled in only less than 30% of the patients treated by drugs. It is thus important to improve this situation first by checking the treatment compliance but also by trying to better educate the hypertensive population about the risk of uncontrolled hypertension and how to decrease this risk. [less ▲]

Detailed reference viewed: 428 (1 ULg)
Full Text
Peer Reviewed
See detailEpidémiologie de l'hypertension artérielle
Krzesinski, Jean-Marie ULg

in Revue Médicale de Liège (2002), 57(3), 142-147

The prevalence of high blood pressure increases in our industrialized society. The main risk factors are hypertensive heredity, small birth weight for the gestational age, large increase of weight in ... [more ▼]

The prevalence of high blood pressure increases in our industrialized society. The main risk factors are hypertensive heredity, small birth weight for the gestational age, large increase of weight in teenagers, low physical activity, excess in salt and/or alcohol consumption. The normotensive people with high normal blood pressure are the future hypertensive population. [less ▲]

Detailed reference viewed: 1025 (7 ULg)
Full Text
See detailHypertension artérielle et artériopathie
Krzesinski, Jean-Marie ULg

in Medi-Sphere (2002)

Detailed reference viewed: 12 (1 ULg)
See detailDu bon usage des antihypertenseurs
Krzesinski, Jean-Marie ULg

Conference (2002, January 17)

Detailed reference viewed: 13 (0 ULg)
Full Text
See detailContrôle de l'hypertension artérielle: peut-on faire mieux?
Krzesinski, Jean-Marie ULg

in Journal de Cardiologie = Tijdschrift voor Cardiologie (2002), 14(5), 180-181

Detailed reference viewed: 7 (0 ULg)
Full Text
See detailImplications pour la communauté d'un meilleur contrôle de la pression artérielle
Krzesinski, Jean-Marie ULg

in Journal de Cardiologie = Tijdschrift voor Cardiologie (2002), 14(5), 186-190

Detailed reference viewed: 9 (0 ULg)
Full Text
See detailL'étude MICROHOPE
Krzesinski, Jean-Marie ULg

in Journal de Cardiologie = Tijdschrift voor Cardiologie (2002), 14(5), 170-172

Detailed reference viewed: 16 (0 ULg)
Full Text
Peer Reviewed
See detailBelgian peer review experience on the Achille's heel in haemodialysis care: vascular access
Theelen, Bernadette ULg; Rorive, Georges ULg; Krzesinski, Jean-Marie ULg et al

in EDTNA/ERCA Journal (2002), 28(4, Oct-Dec), 164-166

AIMS: In order to improve the supervision and to evaluate the quality of care in dialysis units, a national project was promoted as a Peer Review. It consisted of systematic, continuous and critical ... [more ▼]

AIMS: In order to improve the supervision and to evaluate the quality of care in dialysis units, a national project was promoted as a Peer Review. It consisted of systematic, continuous and critical evaluation of the care and the application of international guidelines and compared the reality of care with standards. METHOD: The first chart consisted of the evaluation of infectious episodes of vascular access. This point is particularly relevant since infection represents the second cause of mortality in haemodialysis. A questionnaire concerning each patient was designed. Questions concerned the description of vascular access and the related infectious events. Each questionnaire included 21 items. The project involved 29 dialysis centres, 1,644 patients and 1,775 vascular accesses. The database included 90,525 data. RESULTS: Among the 29 centres, the native arteriovenous fistula (AVF) is the first choice (67.5%) in vascular access, but the proportion of AVF decreases with age contrary to the catheter, which is more frequently chosen, in older patients. Independent of age, 20% of hospitalisations are among patients with catheters and only 7% among patients with AVF. The RR (relative risk) of being hospitalised (any complication of vascular access) is 1.68 for patients with catheters compared to patients with AVF. The rate of infections does not increase with age but is higher for patients with catheters (RR = 2.26). The number of infections appears to be dependent on the staphylococcus aureus carriage in the year. CONCLUSIONS: This first step allows each centre to compare itself to others in an anonymous way. This approach should lead to specific recommendations to improve the quality of care in dialysis units. [less ▲]

Detailed reference viewed: 25 (1 ULg)
Full Text
Peer Reviewed
See detailLes antagonistes calciques ont-ils une place de première ligne dans le traitement de l'hypertension artérielle?
Krzesinski, Jean-Marie ULg

in Revue Médicale de Liège (2002), 57(2), 79-84

During the nineties, a controversy was noted in the literature about the potential risk of using calcium antagonists in the treatment of hypertension. Several recent studies, such as the INSIGHT’s one ... [more ▼]

During the nineties, a controversy was noted in the literature about the potential risk of using calcium antagonists in the treatment of hypertension. Several recent studies, such as the INSIGHT’s one have not confirmed this provided that one uses long-acting molecule. But the real beneficial effect due to the different antihypertensive classes is mainly linked to the magnitude of the blood pressure lowering effect. [less ▲]

Detailed reference viewed: 55 (6 ULg)
Full Text
See detailLe Pr J.-M. Krzesinski (CHU sart Tilman, ULg) a sélectionné pour vous...
Krzesinski, Jean-Marie ULg

in Tempo Médical (2002), 240

Detailed reference viewed: 45 (1 ULg)
Full Text
Peer Reviewed
See detailConfirmation des effets délétères rénaux des AINS anti COX2 illustrée par trois cas cliniques
Piront, P.; Krzesinski, Jean-Marie ULg

in Acta Clinica Belgica (2002), 57(1), 35

Detailed reference viewed: 13 (0 ULg)
Full Text
See detailVers une approche plus efficace du traitement de l'hypertension
Krzesinski, Jean-Marie ULg

in Cardio Spécialistes (2002), 59

Detailed reference viewed: 4 (0 ULg)
See detailLe rein ischémié
Krzesinski, Jean-Marie ULg

Conference (2001, December 11)

Detailed reference viewed: 20 (0 ULg)
See detailHypertension artérielle et accident vasculaire cérébral
Krzesinski, Jean-Marie ULg

Conference (2001, November 15)

Detailed reference viewed: 28 (8 ULg)
See detailEvidence-Based Medicine
Krzesinski, Jean-Marie ULg

Learning material (2001)

Detailed reference viewed: 13 (4 ULg)
Full Text
Peer Reviewed
See detailEtude clinique du mois. Rôle néphroprotecteur des antagonistes du récepteur de l'angiotensine II (ARA) dans le diabète de type 2: résultats des études IDNT et RENAAL
Weekers, Laurent ULg; Krzesinski, Jean-Marie ULg

in Revue Médicale de Liège (2001), 56(10), 723-726

Nephropathy associated with type 2 diabetes mellitus is a rising cause of end-stage renal disease and is a major public health problem. If blocking of the renin angiotensin system has a well established ... [more ▼]

Nephropathy associated with type 2 diabetes mellitus is a rising cause of end-stage renal disease and is a major public health problem. If blocking of the renin angiotensin system has a well established nephroprotective effect in type 1 diabetic nephropathy, this remained to be shown for type 2 diabetes. Two large outcome trials using angiotensin II receptor antagonists (ARA's) in proteinuric chronic renal impairment and hypertensive type 2 diabetic patients have now closed this gap: the Irbesartan Diabetic Nephropathy Trial (IDNT) and the Reduction of Endpoints in NIDDM with Angiotensin II Antagonist Losartan (RENAAL) trial. Both trials showed a significant reduction in the primary pre-specified end-point of death, or worsening of renal function (doubling of serum creatinine) or the development of end-stage renal disease. This effect goes beyond the reduction in blood pressure and makes of ARA's one of the important tools in the treatment of type 2 diabetic nephropathy. [less ▲]

Detailed reference viewed: 327 (1 ULg)